Print this page
-
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).
Protocol: 032002Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Lung -
A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm.
Protocol: 032006Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
The Role of Adaptive Radiation Planning in Patients with Non-Small Cell Lung Cancer on Radiation Induced Toxicity .
Protocol: 032009Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Lung -
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations.
Protocol: 032203Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
Open-Label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC.
Protocol: 032205Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Lung -
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib.
Protocol: 032207Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects with Advanced or Metastatic PD-L1 High [TPS>50%J Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-Lung08) - Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-Line Treatment of Subjects with Advanced or Metastatic NSCLC without Actionable Genomic Alterations.
Protocol: 032211Applicable Disease Sites: Lung
-
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
Protocol: 032212Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
A Prospective Randomized Study of Ramucirumab plus Pembrolizumab versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer.
Protocol: 032304Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
Preoperative Plasma ctDNA Detection in Early Stage Cancer: a Proof-of-Concept Evaluation
Protocol: 032308Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung -
CTEP #10512: A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Protocol: 032309Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Lung -
A Dose Finding Study of CycloSam® (153Sm-DOTMP) to Treat Solid Tumor(s) in the Bone or Metastatic to the Bone (Metastatic Prostate, Breast, and Lung, Osteosarcoma, Ewings Sarcoma, and other solid tumor(s) to the bone all eligible).
Protocol: 052201Principal Investigator:
-
Sanjay Goel
Applicable Disease Sites: Any Site
Breast
Lung
Prostate -
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.
Protocol: 112201Principal Investigator:
-
Scott A Moerdler
Applicable Disease Sites: Bones and Joints
Lung -
ScreenNJ Resource and Evaluation Unit
Protocol: 131820Applicable Disease Sites: Colon
Lung -
TELEhealth Shared decision-making COaching for lung cancer screening in Primary carE (TELESCOPE).
Protocol: 132207Principal Investigator:
-
Anita Y Kinney
Applicable Disease Sites: Lung
- 1
- 2